Lilly’s obesity pill Foundayo sees slower early uptake than Novo’s, with only about 20,000 users in first 20 days

Eli Lilly launched its obesity medication Foundayo recently, and the company reported that roughly 20,000 patients have started the treatment within the first 20 days.

CEO David Ricks said this early uptake is considerably slower than the launch pace observed for Novo Nordisk’s competing obesity drug.

Lilly did not disclose detailed sales figures, leaving investors seeking more precise data on revenue and market share.

Analysts view the modest start as a potential concern for Lilly’s growth expectations in the rapidly expanding obesity market.